子宮內膜癌市場 - 全球產業規模、佔有率、趨勢、機會及預測（按癌症類型、治療方法、診斷方法、最終用途、地區和競爭格局分類，2021-2031年）

全球子宮內膜癌市場預計將從 2025 年的 309 億美元成長到 2031 年的 443.1 億美元，年複合成長率為 6.19%。

該市場涵蓋多種診斷工具和治療方案，包括手術、化療、放射線治療和藥物治療，旨在治療子宮內膜惡性腫瘤。推動市場成長的關鍵因素包括全球肥胖和METABOLIC INC.發病率的上升（這是主要風險因素），以及女性人口老化（女性更容易罹患腫瘤疾病）。此外，標靶藥物療法和免疫療法的出現顯著拓寬了復發性或轉移性疾病患者的治療選擇範圍。根據美國癌症協會的數據，預計2024年美國將新增67,880例宮癌病例，凸顯了對有效治療策略日益成長的臨床需求。

儘管取得了這些進展，但由於新型生物製藥和免疫查核點抑制劑的高昂成本，市場仍面臨許多障礙。在醫療體系注重成本控制的地區，這些高昂的成本往往導致嚴格的報銷審查和使用限制。因此，經濟拮据和醫療資源分配不均成為限制已獲核准治療方法廣泛應用的主要障礙，並可能阻礙其在發展中經濟體的整體市場滲透。

市場促進因素

子宮內膜癌在全球的發生率不斷上升，這主要歸因於肥胖和METABOLIC INC.症候群的增加，也是推動市場擴張的主要因素。過多的脂肪組織會導致雌激素暴露增加，增加子宮惡性腫瘤的風險，尤其是在生活方式正在改變的已開發國家。這種日益嚴重的疾病負擔不僅體現在病例數上，也體現在嚴重的後果上，因此需要緊急的臨床介入。根據美國癌症協會於2024年1月發布的《2024年癌症統計》報告，子宮內膜癌的死亡率正以每年2%的速度成長，使其成為少數幾種死亡率呈上升趨勢的癌症類型之一。這一令人擔憂的趨勢正在加速對先進診斷篩檢和強效治療方案的需求，以便有效管理不斷成長的患者群體。

同時，免疫療法和標靶治療的進步正在改變治療模式，除傳統化療之外的治療方法能夠顯著改善晚期癌症患者的存活預後。近期監管政策的調整擴大了免疫查核點抑制劑的應用範圍，使其適用於更廣泛的患者亞群，包括那些先前只能接受安寧療護的患者。例如，葛蘭素史克（GSK）在2024年8月發布的關於RUBY III期臨床試驗的新聞稿中指出，在一般患者人群中，多斯利單抗聯合化療與單獨化療相比，可降低31%的死亡風險。鑑於癌症的分子異質性，這種治療方法策略的轉變至關重要。Astra Zeneca在2024年6月發布的關於DUO-E臨床試驗的公告中指出，約20%至30%的子宮內膜癌患者存在錯配修復缺陷（dMMR）疾病，這凸顯了市場正朝著基於生物標記的精準醫療方向轉變。

市場挑戰

新型生物製藥和免疫查核點抑制劑的高昂採集費用嚴重阻礙因素了子宮內膜癌市場的成長。這些高昂的價格需要保險公司和政府醫療系統進行嚴格評估，常常導致報銷延遲或被拒絕。因此，對成本較為敏感的地方醫療系統通常會限制將這些昂貴的治療方法納入其標準藥品目錄，從而減少了製藥廠商可觸及的患者群體。

這種經濟負擔直接阻礙了市場發展，減緩了認證核可藥在發展中國家市場和資源匱乏的公共醫療部門的推廣速度。難以獲得穩定的報銷加劇了醫療服務分配的不公平，迫使大量患者依賴成本較低的治療方法。根據美國癌症協會統計，2024年美國約有13,250人死於子宮內膜癌。這些死亡率統計數據凸顯了一個關鍵的差距：先進治療性介入面臨的經濟障礙限制了疾病負擔減輕的潛力，並阻礙了整體市場產生收入。

市場趨勢

定向抗體藥物複合體（ADC）的興起代表著治療領域的一項重要進展，它提供了一種將強效細胞毒性藥物直接遞送至腫瘤相關抗原（如TROP2和HER2）的途徑。對於接受鉑類化療或免疫療法後病情進展的患者而言，這種方法滿足了精準治療方案的迫切需求，避免了標準療法帶來的全身毒性。透過利用特定的生物標記表達，ADC能夠有效干預以往治療選擇有限的晚期疾病。根據2024年8月發表於《ASCO Post》的一篇題為「Sacituzumab govitecan治療進行性子宮內膜癌」的報道，II期TROPiCS-03試驗顯示，在既往接受過治療的進行性子宮內膜癌患者中，sacituzumab govitecan的客觀緩解率達到了22%。

同時，人工智慧在病理學領域的應用正在改變診斷的準確性，它能夠檢測到傳統組織學評估常常遺漏的高風險腫瘤特徵。這些人工智慧工具正在協助精準分子分型的過渡，使臨床醫生能夠根據復發風險對患者進行分層，而不僅依賴改進的分期系統。這項技術的整合對於區分形態相似的腫瘤叢集中的侵襲性亞型至關重要，從而增強個體化治療策略。根據不列顛哥倫比亞大學於2024年6月發表的報導題為《科學家發現高風險子宮內膜癌》的文章，研究人員使用一種新型人工智慧模型成功識別出一種特定的高風險子宮內膜癌亞型，這種亞型無法透過傳統病理學和分子診斷方法檢測到。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球子宮內膜癌市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 癌症類型（子宮內膜癌、子宮肉瘤）
  • 依治療方法（免疫療法、放射線治療、化療、其他治療方法）
  • 透過診斷方法（切片檢查、骨盆超音波、子宮鏡檢查、 電腦斷層掃描、其他診斷方法）
  • 依最終用途（醫院、診斷影像中心、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美子宮內膜癌市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲子宮內膜癌市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區子宮內膜癌市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東與非洲子宮內膜癌市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲子宮內膜癌市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球子宮內膜癌市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Elekta
• Karyopharm Therapeutics Inc.
• Eisai Co., Ltd
• GSK plc
• Siemens Healthineers AG
• Johnson & Johnson
• Boston Scientific Corporation
• Pfizer Inc.
• Bayer AG
• Bristol-Myers Squibb Company

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Endometrial Cancer Market is anticipated to expand from USD 30.90 Billion in 2025 to USD 44.31 Billion by 2031, reflecting a compound annual growth rate of 6.19%. This market encompasses a diverse array of diagnostic tools and therapeutic options, including surgical procedures, chemotherapy, radiation therapy, and pharmacotherapies designed to treat malignancies of the uterine lining. The primary factors propelling market growth are the increasing global incidence of obesity and metabolic syndromes, which are major risk factors, as well as an aging female demographic prone to oncological diseases. Furthermore, the advent of targeted drug therapies and immunotherapies has significantly widened the treatment spectrum for patients suffering from recurrent or metastatic conditions. Data from the American Cancer Society indicates that an estimated 67,880 new cases of uterine cancer were projected for diagnosis in the United States in 2024, underscoring the escalating clinical need for effective management strategies.

Despite these advancements, the market faces a considerable hurdle due to the substantial costs linked to novel biologic agents and immune checkpoint inhibitors. These high expenses frequently result in strict reimbursement evaluations and restricted availability in areas with cost-conscious healthcare frameworks. Consequently, financial constraints and unequal access to medical care act as major impediments that may limit the broad adoption of approved treatments and hinder overall market penetration in developing economic regions.

Market Driver

The escalating global prevalence of endometrial cancer, largely fueled by rising rates of obesity and metabolic syndromes, serves as a primary driver for market expansion. Excess adipose tissue leads to increased estrogen exposure, thereby heightening the risk of malignant uterine conditions, especially in developed countries with changing lifestyle habits. This growing disease burden is evident not only in the number of cases but also in severity outcomes, requiring immediate clinical intervention. According to the 'Cancer Statistics, 2024' report by the American Cancer Society in January 2024, mortality rates for uterine corpus cancer are rising by 2% annually, identifying it as one of the few cancer types with increasing death rates. This concerning trend accelerates the demand for advanced diagnostic screenings and robust therapeutic measures to effectively manage the growing patient population.

Concurrently, progress in immunotherapy and targeted therapeutics is transforming treatment paradigms, transitioning beyond conventional chemotherapy to provide better survival outcomes for advanced disease stages. Recent regulatory achievements have extended the use of immune checkpoint inhibitors to a wider range of patient subgroups, including those who previously had only palliative options. For example, a press release from GSK in August 2024 regarding the RUBY phase III trial highlighted that combining dostarlimab with chemotherapy resulted in a 31% reduction in the risk of death compared to chemotherapy alone in the general patient population. This evolution in therapy is vital given the molecular heterogeneity of the cancer; an AstraZeneca announcement in June 2024 concerning the DUO-E trial noted that approximately 20% to 30% of endometrial cancer patients have mismatch repair deficient (dMMR) disease, emphasizing the significant market shift toward precision medicine based on biomarkers.

Market Challenge

The substantial acquisition costs associated with new biologic agents and immune checkpoint inhibitors function as a major constraint on the growth of the endometrial cancer market. These high prices require intense evaluation by insurance providers and government healthcare schemes, often leading to delays or denials of reimbursement coverage. As a result, healthcare systems in regions sensitive to costs frequently limit the inclusion of these premium therapies in their standard drug lists, thereby reducing the accessible patient population for pharmaceutical manufacturers.

This economic strain directly impedes market development by slowing the uptake of approved drugs in developing markets and under-resourced public health sectors. The difficulty in obtaining consistent reimbursement results in unequal care delivery, leaving a large segment of the patient population dependent on older, less costly treatment methods. According to the American Cancer Society, approximately 13,250 deaths from uterine body cancers were projected to occur in the United States in 2024. This mortality statistic highlights a critical gap where financial barriers to advanced therapeutic interventions restrict the potential for reducing disease burden and limit overall market revenue generation.

Market Trends

The rise of Antibody-Drug Conjugates (ADCs) for targeted delivery marks a significant evolution in the therapeutic landscape, offering a method to transport potent cytotoxic agents directly to tumor-associated antigens like TROP2 and HER2. This approach addresses a crucial unmet need for patients whose disease progresses following platinum-based chemotherapy and immunotherapy, providing a precise alternative to the systemic toxicities of standard treatments. By utilizing specific biomarker expression, ADCs facilitate effective intervention in advanced disease scenarios where options were previously restricted. As reported by The ASCO Post in August 2024 regarding the 'Sacituzumab Govitecan in Advanced Endometrial Cancer' report, the phase II TROPiCS-03 trial showed that sacituzumab govitecan achieved an objective response rate of 22% in patients with advanced endometrial cancer who had undergone prior therapies.

Simultaneously, the application of artificial intelligence in pathology is transforming diagnostic precision by detecting high-risk tumor characteristics that often evade traditional histological evaluation. These AI-powered tools assist in the shift toward accurate molecular classification, enabling clinicians to categorize patients based on recurrence risk more effectively than improved staging systems alone. This integration of technology is essential for differentiating aggressive subtypes within morphologically similar tumor clusters, thereby enhancing personalized care strategies. According to a June 2024 article from the University of British Columbia titled 'Scientists discover high-risk form of endometrial cancer,' researchers employed a new AI model to identify a specific high-risk subset of endometrial cancer that would otherwise remain undetected by conventional pathology and molecular diagnostics.

Key Market Players

• Elekta
• Karyopharm Therapeutics Inc.
• Eisai Co., Ltd
• GSK plc
• Siemens Healthineers AG
• Johnson & Johnson
• Boston Scientific Corporation
• Pfizer Inc.
• Bayer AG
• Bristol-Myers Squibb Company

Report Scope

In this report, the Global Endometrial Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Endometrial Cancer Market, By Cancer Type

• Endometrial Carcinoma
• Uterine Sarcomas

Endometrial Cancer Market, By Therapy

• Immunotherapy
• Radiation Therapy
• Chemotherapy
• Other Types of Therapies

Endometrial Cancer Market, By Diagnosis Method

• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• CT scan
• Other Diagnosis Methods

Endometrial Cancer Market, By End Use

• Hospitals
• Imaging Centers
• Others

Endometrial Cancer Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Endometrial Cancer Market.

Available Customizations:

Global Endometrial Cancer Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Endometrial Cancer Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Endometrial Carcinoma, Uterine Sarcomas)
  • 5.2.2. By Therapy (Immunotherapy, Radiation Therapy, Chemotherapy, Other Types of Therapies)
  • 5.2.3. By Diagnosis Method (Biopsy, Pelvic Ultrasound, Hysteroscopy, CT scan, Other Diagnosis Methods)
  • 5.2.4. By End Use (Hospitals, Imaging Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Endometrial Cancer Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Therapy
  • 6.2.3. By Diagnosis Method
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Endometrial Cancer Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Therapy
      • 6.3.1.2.3. By Diagnosis Method
      • 6.3.1.2.4. By End Use
  • 6.3.2. Canada Endometrial Cancer Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Therapy
      • 6.3.2.2.3. By Diagnosis Method
      • 6.3.2.2.4. By End Use
  • 6.3.3. Mexico Endometrial Cancer Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Therapy
      • 6.3.3.2.3. By Diagnosis Method
      • 6.3.3.2.4. By End Use

7. Europe Endometrial Cancer Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Therapy
  • 7.2.3. By Diagnosis Method
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Endometrial Cancer Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Therapy
      • 7.3.1.2.3. By Diagnosis Method
      • 7.3.1.2.4. By End Use
  • 7.3.2. France Endometrial Cancer Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Therapy
      • 7.3.2.2.3. By Diagnosis Method
      • 7.3.2.2.4. By End Use
  • 7.3.3. United Kingdom Endometrial Cancer Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Therapy
      • 7.3.3.2.3. By Diagnosis Method
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Endometrial Cancer Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By Therapy
      • 7.3.4.2.3. By Diagnosis Method
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Endometrial Cancer Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By Therapy
      • 7.3.5.2.3. By Diagnosis Method
      • 7.3.5.2.4. By End Use

8. Asia Pacific Endometrial Cancer Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Therapy
  • 8.2.3. By Diagnosis Method
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Endometrial Cancer Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Therapy
      • 8.3.1.2.3. By Diagnosis Method
      • 8.3.1.2.4. By End Use
  • 8.3.2. India Endometrial Cancer Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Therapy
      • 8.3.2.2.3. By Diagnosis Method
      • 8.3.2.2.4. By End Use
  • 8.3.3. Japan Endometrial Cancer Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Therapy
      • 8.3.3.2.3. By Diagnosis Method
      • 8.3.3.2.4. By End Use
  • 8.3.4. South Korea Endometrial Cancer Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Type
      • 8.3.4.2.2. By Therapy
      • 8.3.4.2.3. By Diagnosis Method
      • 8.3.4.2.4. By End Use
  • 8.3.5. Australia Endometrial Cancer Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Type
      • 8.3.5.2.2. By Therapy
      • 8.3.5.2.3. By Diagnosis Method
      • 8.3.5.2.4. By End Use

9. Middle East & Africa Endometrial Cancer Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Therapy
  • 9.2.3. By Diagnosis Method
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Endometrial Cancer Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Therapy
      • 9.3.1.2.3. By Diagnosis Method
      • 9.3.1.2.4. By End Use
  • 9.3.2. UAE Endometrial Cancer Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Therapy
      • 9.3.2.2.3. By Diagnosis Method
      • 9.3.2.2.4. By End Use
  • 9.3.3. South Africa Endometrial Cancer Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Therapy
      • 9.3.3.2.3. By Diagnosis Method
      • 9.3.3.2.4. By End Use

10. South America Endometrial Cancer Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By Therapy
  • 10.2.3. By Diagnosis Method
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Endometrial Cancer Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By Therapy
      • 10.3.1.2.3. By Diagnosis Method
      • 10.3.1.2.4. By End Use
  • 10.3.2. Colombia Endometrial Cancer Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By Therapy
      • 10.3.2.2.3. By Diagnosis Method
      • 10.3.2.2.4. By End Use
  • 10.3.3. Argentina Endometrial Cancer Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By Therapy
      • 10.3.3.2.3. By Diagnosis Method
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Endometrial Cancer Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Elekta
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Karyopharm Therapeutics Inc.
• 15.3. Eisai Co., Ltd
• 15.4. GSK plc
• 15.5. Siemens Healthineers AG
• 15.6. Johnson & Johnson
• 15.7. Boston Scientific Corporation
• 15.8. Pfizer Inc.
• 15.9. Bayer AG
• 15.10. Bristol-Myers Squibb Company

16. Strategic Recommendations

17. About Us & Disclaimer